Omalizumab

Some monoclonal antibodies used in the treatment of inadequately controlled severe asthma may pose anaphylactic risks, according to a retrospective study of post-marking surveillance data published in Clinical and Translational Allergy.

The FDA has approved a self-injectable formulation of Xolair for appropriate patients with moderate to severe persistent allergic asthma, nasal polyps or chronic idiopathic urticaria, according to the manufacturers.

In a new study, adherence to asthma biologic therapy was higher than adherence to inhaled corticosteroids among adults with asthma.

Use of biologic therapies in patients with severe, uncontrolled asthma treated by subspecialists in the United States is common, according to data from the real-world, observational CHRONICLE study.

Omalizumab may effectively treat food allergy symptoms in patients with alpha-gal syndrome, according to research from a small study that was to be presented at the American Academy of Asthma, Allergy & Immunology Annual Meeting.

HOUSTON — Xolair signicantly improved nasal congestion and nasal polyp scores in patients with corticosteroid-refractory nasal polyps, according to data from two phase 3 trials presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

Methotrexate may be used as a third-line therapy for treating chronic spontaneous urticaria, but it was not superior to placebo added to H1-antihistamines, according to a research letter in the Journal of the American Academy of Dermatology.